Gilles Montalescot, ESC 2021 – the QUORUM Clinical Study
Prof. Gilles Montalescot (Professor, Pitié-Salpêtrière Hospital, Paris, France) kindly shared his thoughts on the difficulty of treating heart failure after acute myocardial infarction, the use of firibastat and the QUORUM clinical study (NCT03715998) from the virtual ESC Congress 2021.
- Why does heart failure after acute myocardial infarction remain so challenging to treat? (0.19)
- Could you tell us a little about firibastat and the rationale for its potential use in heart failure post myocardial infarction? (1.44)
- What were the aims and design of the QUORUM clinical study? (3.00)
- What were the efficacy and safety endpoints and how well were they achieved? (4.36)
- What will be the clinical impact of these findings? (7.13)
Speaker disclosures: Prof. Gilles Montalescot declares research funds for the Institution or fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cell Prothera, CSL Behring, Europa, Idorsia, IRIS -Servier, Medtronic, MSD, Novartis, Pfizer, Quantum Genomics and Sanofi-Aventis.
Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.
Filmed during a remote video call with Prof. Gilles Montalescot as a highlight of ESC 2021, August 2021.
Share this Video
Related Videos In Heart Failure
John Boehmer, ACC 2023: The MicrocorTM device for heart failure management, the BMAD trial
Rates of readmission following heart failure hospitalization are high. The BMAD trial in patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Barry Borlaug, ACC 2023: Dapagliflozin in heart failure, an invasive hemodynamic randomized trial
Heart failure with preserved ejection fraction (HFpEF) is a hemodynamic disorder characterized by an elevation of left ventricular filling pressures. This trial assessed the ability of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), to reduce this elevation. In this touchCARDIO interview, we speak with Dr Barry Borlaug (Mayo Clinic, Rochester, MN, USA) to discuss the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!